S&P 500   3,358.24 (+1.81%)
DOW   27,692.94 (+1.91%)
QQQ   276.29 (+1.74%)
AAPL   114.64 (+2.10%)
MSFT   209.51 (+0.81%)
FB   256.19 (+0.54%)
GOOGL   1,459.13 (+1.39%)
AMZN   3,164.68 (+2.25%)
TSLA   417.93 (+2.60%)
NVDA   516.77 (+0.35%)
BABA   276.07 (+1.84%)
CGC   14.26 (+0.64%)
GE   6.24 (+2.13%)
MU   49.29 (+0.31%)
AMD   78.76 (+0.90%)
T   28.55 (+1.82%)
F   6.71 (+3.07%)
ACB   4.84 (-4.16%)
GILD   62.84 (+0.95%)
NFLX   486.00 (+0.65%)
DIS   126.27 (+1.83%)
BAC   24.22 (+3.11%)
BA   165.64 (+6.16%)
S&P 500   3,358.24 (+1.81%)
DOW   27,692.94 (+1.91%)
QQQ   276.29 (+1.74%)
AAPL   114.64 (+2.10%)
MSFT   209.51 (+0.81%)
FB   256.19 (+0.54%)
GOOGL   1,459.13 (+1.39%)
AMZN   3,164.68 (+2.25%)
TSLA   417.93 (+2.60%)
NVDA   516.77 (+0.35%)
BABA   276.07 (+1.84%)
CGC   14.26 (+0.64%)
GE   6.24 (+2.13%)
MU   49.29 (+0.31%)
AMD   78.76 (+0.90%)
T   28.55 (+1.82%)
F   6.71 (+3.07%)
ACB   4.84 (-4.16%)
GILD   62.84 (+0.95%)
NFLX   486.00 (+0.65%)
DIS   126.27 (+1.83%)
BAC   24.22 (+3.11%)
BA   165.64 (+6.16%)
S&P 500   3,358.24 (+1.81%)
DOW   27,692.94 (+1.91%)
QQQ   276.29 (+1.74%)
AAPL   114.64 (+2.10%)
MSFT   209.51 (+0.81%)
FB   256.19 (+0.54%)
GOOGL   1,459.13 (+1.39%)
AMZN   3,164.68 (+2.25%)
TSLA   417.93 (+2.60%)
NVDA   516.77 (+0.35%)
BABA   276.07 (+1.84%)
CGC   14.26 (+0.64%)
GE   6.24 (+2.13%)
MU   49.29 (+0.31%)
AMD   78.76 (+0.90%)
T   28.55 (+1.82%)
F   6.71 (+3.07%)
ACB   4.84 (-4.16%)
GILD   62.84 (+0.95%)
NFLX   486.00 (+0.65%)
DIS   126.27 (+1.83%)
BAC   24.22 (+3.11%)
BA   165.64 (+6.16%)
S&P 500   3,358.24 (+1.81%)
DOW   27,692.94 (+1.91%)
QQQ   276.29 (+1.74%)
AAPL   114.64 (+2.10%)
MSFT   209.51 (+0.81%)
FB   256.19 (+0.54%)
GOOGL   1,459.13 (+1.39%)
AMZN   3,164.68 (+2.25%)
TSLA   417.93 (+2.60%)
NVDA   516.77 (+0.35%)
BABA   276.07 (+1.84%)
CGC   14.26 (+0.64%)
GE   6.24 (+2.13%)
MU   49.29 (+0.31%)
AMD   78.76 (+0.90%)
T   28.55 (+1.82%)
F   6.71 (+3.07%)
ACB   4.84 (-4.16%)
GILD   62.84 (+0.95%)
NFLX   486.00 (+0.65%)
DIS   126.27 (+1.83%)
BAC   24.22 (+3.11%)
BA   165.64 (+6.16%)
Log in
NASDAQ:ACOR

Acorda Therapeutics Stock Forecast, Price & News

$0.61
0.00 (-0.05 %)
(As of 09/28/2020 02:03 PM ET)
Add
Compare
Today's Range
$0.55
Now: $0.61
$0.73
50-Day Range
$0.45
MA: $0.57
$0.76
52-Week Range
$0.42
Now: $0.61
$3.10
Volume775,305 shs
Average Volume2.59 million shs
Market Capitalization$29.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Read More
Acorda Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACOR
CUSIP00484M10
Phone914-347-4300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$192.41 million
Cash Flow$4.73 per share
Book Value$6.47 per share

Profitability

Net Income$-272,970,000.00
Net Margins-138.66%

Miscellaneous

Employees474
Market Cap$29.49 million
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$0.61
0.00 (-0.05 %)
(As of 09/28/2020 02:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

How has Acorda Therapeutics' stock been impacted by Coronavirus?

Acorda Therapeutics' stock was trading at $1.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACOR shares have decreased by 41.4% and is now trading at $0.5915.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Acorda Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Acorda Therapeutics
.

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Acorda Therapeutics
.

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics Inc (NASDAQ:ACOR) released its quarterly earnings data on Tuesday, August, 4th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.27. The biopharmaceutical company earned $33.62 million during the quarter, compared to the consensus estimate of $26.35 million. Acorda Therapeutics had a negative return on equity of 19.55% and a negative net margin of 138.66%.
View Acorda Therapeutics' earnings history
.

What price target have analysts set for ACOR?

4 brokerages have issued 1 year price objectives for Acorda Therapeutics' stock. Their forecasts range from $1.00 to $10.00. On average, they anticipate Acorda Therapeutics' stock price to reach $4.35 in the next twelve months. This suggests a possible upside of 635.4% from the stock's current price.
View analysts' price targets for Acorda Therapeutics
.

Are investors shorting Acorda Therapeutics?

Acorda Therapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 11,000,000 shares, an increase of 9.8% from the August 15th total of 10,020,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the days-to-cover ratio is presently 5.2 days. Currently, 23.3% of the company's shares are short sold.
View Acorda Therapeutics' Short Interest
.

Who are some of Acorda Therapeutics' key competitors?

What other stocks do shareholders of Acorda Therapeutics own?

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the following people:
  • Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 63)
  • Mr. David Lawrence, Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer (Age 61)
  • Ms. Lauren M. Sabella, Chief Commercial Officer (Age 58)
  • Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 46)
  • Dr. Burkhard Blank, Chief Medical Officer and Head of R&D (Age 64)

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (3.90%), AQR Capital Management LLC (2.00%), Federated Hermes Inc. (1.38%), Bridgeway Capital Management Inc. (0.72%), Jane Street Group LLC (0.54%) and Charles Schwab Investment Management Inc. (0.40%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Jane Wasman, Lauren M Sabella, Lorin Randall, Ron Cohen and Scopia Capital Management Lp.
View institutional ownership trends for Acorda Therapeutics
.

Which major investors are selling Acorda Therapeutics stock?

ACOR stock was sold by a variety of institutional investors in the last quarter, including Charles Schwab Investment Management Inc.. Company insiders that have sold Acorda Therapeutics company stock in the last year include Jane Wasman, and Ron Cohen.
View insider buying and selling activity for Acorda Therapeutics
.

Which major investors are buying Acorda Therapeutics stock?

ACOR stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Jane Street Group LLC, Federated Hermes Inc., Bridgeway Capital Management Inc., AQR Capital Management LLC, Bank of America Corp DE, Blair William & Co. IL, and Russell Investments Group Ltd..
View insider buying and selling activity for Acorda Therapeutics
.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $0.59.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $28.37 million and generates $192.41 million in revenue each year. The biopharmaceutical company earns $-272,970,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Acorda Therapeutics employs 474 workers across the globe.

What is Acorda Therapeutics' official website?

The official website for Acorda Therapeutics is www.acorda.com.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.